# Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer

> **NCT01071915** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 157 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix 240/80 mg

## Key facts

- **NCT ID:** NCT01071915
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2013-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01071915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01071915, "Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01071915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*